Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Lisa M. Kopp"'
Autor:
Lisa M. Kopp, Richard B. Womer, Cindy L. Schwartz, David H. Ebb, Vivian I. Franco, David Hall, Donald A. Barkauskas, Mark D. Krailo, Holcombe E. Grier, Paul A. Meyers, Leonard H. Wexler, Neyssa M. Marina, Katherine A. Janeway, Richard Gorlick, Mark L. Bernstein, Steven E. Lipshultz, for the Children’s Oncology Group
Publikováno v:
Cardio-Oncology, Vol 5, Iss 1, Pp 1-12 (2019)
Abstract Background Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown. Methods We evaluated children with oste
Externí odkaz:
https://doaj.org/article/c1df26e926ca40859f1f7499883d65cd
Autor:
Eric J. Chow, Sanjeev Aggarwal, David R. Doody, Richard Aplenc, Saro H. Armenian, K. Scott Baker, Smita Bhatia, Nancy Blythe, Steven D. Colan, Louis S. Constine, David R. Freyer, Lisa M. Kopp, Caroline Laverdière, Wendy M. Leisenring, Nao Sasaki, Lynda M. Vrooman, Barbara L. Asselin, Cindy L. Schwartz, Steven E. Lipshultz
Publikováno v:
Journal of Clinical Oncology. 41:2248-2257
PURPOSE For survivors of childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years. However, longer-term data are lacking. METHODS Within the Children's Oncology Group and the Dana Farber Cancer Institute's Child
Autor:
Susan L. Whiteway, Aaron R. Weiss, Safia K. Ahmed, Wendy A. Allen-Rhoades, Viswatej Avutu, Kenneth Cardona, Lara E. Davis, Elizabeth J. Davis, Daniel J. Indelicato, Michael S. Isakoff, Katherine A. Janeway, J. Andrew Livingston, Shreyaskumar R. Patel, Damon R. Reed, Richard F. Riedel, Katherine A. Thornton, Lisa M. Kopp
Publikováno v:
Journal of Adolescent and Young Adult Oncology.
Autor:
Cindy L. Schwartz, Steven E. Lipshultz, Emma R. Lipshultz, Lynda M. Vrooman, Eric J. Chow, David R. Doody, Saro H. Armenian, Barbara L. Asselin, Louis S. Constine, David R. Freyer, K. Scott Baker, Lisa M. Kopp, Smita Bhatia
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:536-542
Background: Childhood cancer survivors are at risk for cardiovascular disease. We assessed the burden of potentially modifiable cardiometabolic risk factors (CRF) among survivors compared with population-matched controls. Methods: Survivors previousl
Autor:
Louis S. Constine, Lisa M. Kopp, Smita Bhatia, Cindy L. Schwartz, David R. Freyer, Steven E. Lipshultz, David R. Doody, Richard Aplenc, Lynda M. Vrooman, Saro H. Armenian, K. Scott Baker, Sanjeev Aggarwal, Wendy M. Leisenring, Eric J. Chow, Barbara L. Asselin, Yuan-Shung Huang
Publikováno v:
Cancer
Background The objective of this study was to examine long-term outcomes among children newly diagnosed with cancer who were treated in dexrazoxane-containing clinical trials. Methods P9404 (acute lymphoblastic leukemia/lymphoma [ALL]), P9425 and P94
Autor:
Bree R. Eaton, Wendy Allen-Rhoades, Katherine Anne Thornton, Katherine A. Janeway, Safia K. Ahmed, Shreyaskumar Patel, Damon R. Reed, Yen-Lin Chen, Thomas J. Scharschmidt, Denise K. Reinke, Aaron R. Weiss, Dian Wang, R. Lor Randall, Richard F. Riedel, Douglas S. Hawkins, Lisa M. Kopp, Viswatej Avutu, Lara E. Davis, Daniel J. Indelicato
Publikováno v:
Journal of adolescent and young adult oncology, vol 11, iss 3
J Adolesc Young Adult Oncol
J Adolesc Young Adult Oncol
ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Trials Network study codeveloped by pediatric and adult consortia with two treatment cohorts. We report on the findings of a survey to identify barriers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a064d0834b44659d5de058623feeffb6
https://escholarship.org/uc/item/9fs9m9nj
https://escholarship.org/uc/item/9fs9m9nj
Publikováno v:
J Adolesc Young Adult Oncol
PURPOSE: The aim of this study was to describe diet and physical activity (PA) behaviors and health beliefs among cancer survivors and identify potential differences between adolescent and young adult (AYA) and adult/older cancer survivors. METHODS:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760fcf8341c30b91beb0fac38d0bb94f
https://europepmc.org/articles/PMC9529365/
https://europepmc.org/articles/PMC9529365/
Autor:
Tracy E. Crane, Lisa M. Kopp, Carol L. Howe, Cynthia A. Thomson, Meghan B. Skiba, Jennifer J. McElfresh, Elizabeth T. Jacobs
Publikováno v:
Journal of Adolescent and Young Adult Oncology. 9:315-327
Adolescent and young adult (AYA) cancer survivors, here defined as individuals diagnosed with cancer between 15 and 39 years of age, are at high risk for adverse late-term metabolic effects of treatment through adulthood. Diet is a modifiable lifesty
Autor:
Lisa M. Kopp, Elizabeth Crowley, Thomas Hawthorne, Jeffrey A. Moscow, Joel M. Reid, Yun Gao, Victor M. Villalobos, R. Lor Randall, Richard Gorlick, Katherine A. Janeway, Suman Malempati, Mark Krailo, Brenda J. Weigel, Allen Buxton
Publikováno v:
European Journal of Cancer. 121:177-183
BackgroundThe prognosis is poor for children and adolescents with recurrent osteosarcoma (OS). Glycoprotein non-metastatic B (gpNMB) is a glycoprotein highly expressed in OS cells. We conducted a phase II study of glembatumumab vedotin (GV), a fully
Autor:
Cindy L. Schwartz, Richard Gorlick, David H. Ebb, Donald A. Barkauskas, Paul A. Meyers, Leonard H. Wexler, Lisa M. Kopp, Neyssa Marina, Mark Krailo, Mark L. Bernstein, Vivian I. Franco, Steven E. Lipshultz, David Hall, Holcombe E. Grier, Richard B. Womer, Katherine A. Janeway
Publikováno v:
Cardio-Oncology, Vol 5, Iss 1, Pp 1-12 (2019)
Cardio-oncology
Cardio-oncology
Background Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown. Methods We evaluated children with osteosarcoma